Indirect evidence for early widespread gray matter involvement in relapsing–remitting multiple sclerosis

Multiple sclerosis (MS) has traditionally been viewed as an inflammatory demyelinating white matter (WM) disease of the central nervous system. However, recent pathology and MRI studies have shown lesions in the gray matter (GM) as well. To ascertain the extent of GM involvement, we obtained with nonlocalizing proton MR spectroscopy the concentration of N-acetylaspartate (NAA), a metabolite found almost exclusively in neuronal cells, T2-lesion loads, and GM and WM fractions in the entire brain of 71 relapsing-remitting (RR) MS patients (51 women, 20 men, 25-55 years old) and 41 healthy controls (27 women, 14 men, 23-55 years old). The average whole-brain NAA (WBNAA) difference between the patients and the controls was -2.9 mM (-22%, P < 0.0001); range: +1.2 to -7.8 mM (+8% to -63%). The patients' median T2 lesion volume was 5.5 (range: 0.140-28) cm(3). GM and WM comprised 50.4 +/- 3.8% and 30.4 +/- 5.0% (mean +/- standard deviation), respectively, of the total brain volume in the patients; 53.8 +/- 3.7% and 35.4 +/- 4.7% in the controls. Because WM and GM constitute approximately 40% and 60% of the brain parenchyma, respectively, and the NAA concentration in the former is 2/3 of the latter, WBNAA loss greater than 40% x 2/3 = 27% cannot be explained in terms of WM (axonal) pathology alone and must include widespread GM (neuronal) deficits. Therefore, the concept of MS, even at its earlier stages, as a WM disease might need to be reexamined.

[1]  Peter Kapeller,et al.  Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study , 2001, Journal of Neurology.

[2]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[3]  B. Trapp,et al.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.

[4]  Ludwin Sk,et al.  The neuropathology of multiple sclerosis. , 2000 .

[5]  P M Matthews,et al.  Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. , 1996, Brain : a journal of neurology.

[6]  F Barkhof,et al.  Neuronal damage in T1‐hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy , 1999, Annals of neurology.

[7]  M Cercignani,et al.  Diffusion tensor magnetic resonance imaging in multiple sclerosis , 2001, Neurology.

[8]  B. Brown.  Proceedings of the Society of Photo-optical Instrumentation Engineers , 1975 .

[9]  P. M. Matthews,et al.  Evidence of early cortical atrophy in MS , 2003, Neurology.

[10]  J. Udupa,et al.  A new computer-assisted method for the quantification of enhancing lesions in multiple sclerosis. , 1997, Journal of computer assisted tomography.

[11]  Oded Gonen,et al.  Reproducibility of 3D proton spectroscopy in the human brain , 2002, Magnetic resonance in medicine.

[12]  P M Matthews,et al.  Proton MR spectroscopy in multiple sclerosis. , 2000, Neuroimaging clinics of North America.

[13]  Stephen M. Rao,et al.  Cognitive dysfunction in multiple sclerosis. , 1991, Neurology.

[14]  J S Wolinsky,et al.  Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging , 2001, Multiple sclerosis.

[15]  Shrikanth S. Narayanan,et al.  Imaging axonal damage in multiple sclerosis by means of MR spectroscopy , 2000, Neurological Sciences.

[16]  R. Kinkel,et al.  Axonal loss in normal-appearing white matter in a patient with acute MS , 2001, Neurology.

[17]  Shi-Jiang Li,et al.  Differentiation of metabolic concentrations between gray matter and white matter of human brain by in vivo 1H magnetic resonance spectroscopy , 1998, Magnetic resonance in medicine.

[18]  R I Grossman,et al.  Total brain N‐acetylaspartate concentration in normal, age‐grouped females: Quantitation with non‐echo proton NMR spectroscopy , 1998, Magnetic resonance in medicine.

[19]  J K Udupa,et al.  Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. , 2000, Radiology.

[20]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[21]  A J Thompson,et al.  Brain atrophy in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.

[22]  R I Grossman,et al.  Total brain N-acetylaspartate , 2000, Neurology.

[23]  J. Coyle,et al.  Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies , 1991, Neuroscience.

[24]  Jayaram K. Udupa,et al.  System for the comprehensive analysis of multiple sclerosis lesion load based on MR imagery , 1997, Medical Imaging.

[25]  Supun Samarasekera,et al.  Fuzzy Connectedness and Object Definition: Theory, Algorithms, and Applications in Image Segmentation , 1996, CVGIP Graph. Model. Image Process..

[26]  M. Blinkenberg,et al.  Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS , 2000, Neurology.

[27]  J K Udupa,et al.  Differences between relapsing-remitting and chronic progressive multiple sclerosis as determined with quantitative MR imaging. , 1999, Radiology.

[28]  J K Udupa,et al.  Magnetization transfer ratio histogram analysis of gray matter in relapsing-remitting multiple sclerosis. , 2001, AJNR. American journal of neuroradiology.

[29]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.

[30]  Dewey Odhner,et al.  3DVIEWNIX: an open, transportable, multidimensional, multimodality, multiparametric imaging software system , 1994, Medical Imaging.

[31]  P M Matthews,et al.  Imaging axonal damage of normal-appearing white matter in multiple sclerosis. , 1998, Brain : a journal of neurology.

[32]  M Rovaris,et al.  Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. , 2003, Brain : a journal of neurology.

[33]  R I Grossman,et al.  Microscopic disease in normal-appearing white matter on conventional MR images in patients with multiple sclerosis: assessment with magnetization-transfer measurements. , 1995, Radiology.

[34]  J K Udupa,et al.  Relapsing-remitting multiple sclerosis: longitudinal analysis of MR images--lack of correlation between changes in T2 lesion volume and clinical findings. , 1999, Radiology.

[35]  J. Townsend,et al.  Normal brain development and aging: quantitative analysis at in vivo MR imaging in healthy volunteers. , 2000, Radiology.

[36]  F. Barkhof,et al.  Cortical lesions in multiple sclerosis. , 1999, Brain : a journal of neurology.

[37]  P M Matthews,et al.  Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease , 1990, Magnetic resonance in medicine.

[38]  B. Brownell,et al.  The distribution of plaques in the cerebrum in multiple sclerosis , 1962, Journal of neurology, neurosurgery, and psychiatry.

[39]  P. Matthews,et al.  Thalamic neurodegeneration in multiple sclerosis , 2002, Annals of neurology.

[40]  G J Barker,et al.  Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. , 1994, Brain : a journal of neurology.

[41]  P Kapeller,et al.  Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.

[42]  J S Wolinsky,et al.  Serial proton magnetic resonance spectroscopic imaging, contrast‐enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis , 1998, Annals of neurology.

[43]  Massimo Filippi,et al.  Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. , 2002, AJNR. American journal of neuroradiology.

[44]  I. Allen,et al.  A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis , 1979, Journal of the Neurological Sciences.

[45]  Nikos Evangelou,et al.  Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis , 2000, Annals of neurology.

[46]  R. Rudick,et al.  Neurological disability correlates with spinal cord axonal loss and reduced N‐acetyl aspartate in chronic multiple sclerosis patients , 2000, Annals of neurology.